Cleveland Clinic Journal of Medicine : March 2023 - CD
Adverse events per 100 patient-years of exposure | Download Scientific Diagram
Exposure-adjusted rates (per 100 patient-years) of common... | Download Table
Incidence of serious adverse events per 100 patient-years in the UPLIFT... | Download Table
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | NEJM
incidence rate (events/100 patient-years) of AE and ADR classifi ed by... | Download Scientific Diagram
Adverse Events Incidence Rates
incidence rate (events/100 patient-years) of AE and ADR classifi ed by... | Download Scientific Diagram
Treatment-emergent adverse events per 100 patient-years by years of... | Download Scientific Diagram
RA | Safety Data & Possible Side Effects | RITUXAN® (rituximab)
Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial - ACR Meeting Abstracts
Adverse Event Rates Per 100 Patient-Years of Follow-Up | Download Table
Rates (per 100 patient years) for individual end-points. | Download Table
Cleveland Clinic Journal of Medicine : September 2021 - CD
Event rates per 100 patient-years follow-up (number of events) | Download Table
Tezepelumab shows long-term safety, efficacy for severe asthma
Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo. - ppt download
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment | The Journal of Rheumatology
Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis
Adverse events of special interest per 100 patient-years during the... | Download Scientific Diagram
Adalimumab trials show low rate of IBD adverse events
Event rate (per 100 patient-years) and risk of study endpoints... | Download Scientific Diagram
exposure-adjusted Aes through week 52 (event rate per 100 patient-years) | Download Table
Exposure-adjusted rates (per 100 patient-years) of common... | Download Table
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure | SpringerLink
